Asset Details
Do you wish to reserve the book?
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Do you wish to request the book?
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008
Overview
The triple chemotherapy with epirubicin plus cisplatin and fluorouracil is standard for advanced esophagogastric cancer. The fluorouracil must be infused through an ambulatory infusion pump, which impairs the quality of life; cisplatin, which is nephrotoxic, requires intravenous hydration. In this randomized trial, capecitabine, an oral fluoropyrimidine, plus oxaliplatin, a platinum compound that does not require hydration, was as effective in prolonging overall survival as was fluorouracil plus cisplatin.
Capecitabine, an oral fluoropyrimidine, plus oxaliplatin, a platinum compound that does not require hydration, was as effective in prolonging overall survival as was fluorouracil plus cisplatin.
Gastric and esophageal cancers are the second and sixth most common causes of cancer-related deaths worldwide, respectively.
1
Most patients present with advanced, inoperable, or metastatic disease, and 5-year survival rates are approximately 10 to 15%. Palliative chemotherapy for advanced disease improves survival, as compared with the best supportive care.
2
–
4
There is no single, global standard regimen for the first-line treatment of advanced disease. Of the available regimens, the regimen containing epirubicin, cisplatin, and infused fluorouracil (ECF) is widely used in Europe, particularly in the United Kingdom, on the basis of the results of two randomized studies
5
,
6
and a . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biological and medical sciences
/ Cisplatin - administration & dosage
/ Deoxycytidine - administration & dosage
/ Deoxycytidine - analogs & derivatives
/ Epirubicin - administration & dosage
/ Esophageal Neoplasms - drug therapy
/ Esophageal Neoplasms - mortality
/ Female
/ Fluorouracil - administration & dosage
/ Fluorouracil - analogs & derivatives
/ Humans
/ Male
/ Organoplatinum Compounds - administration & dosage
/ Stomach Neoplasms - drug therapy
